Top Stories
Up to 71% of clinically significant lung nodules lack appropriate follow-up, while high-risk pulmonary embolism patients can face treatment delays.
The pharma will use Tempus' Lens platform to pressure-test trial assumptions and stratify patient groups across five initial programmes spanning solid tumours and Alzheimer's disease.
The companies expect the initiative to test roughly 7000 breast and lung cancer patients annually.
The drugmaker will use Headlamp's Lumos AI platform to speed up the development of azeliragon for the treatment of severe depression and fatigue in patients with MS.
The partners will launch prospective trial to assess whether Brainomix's e-Lung software can shift timing of pulmonary fibrosis diagnosis and treatment.
Conference News
Ahead of ASCO 2026, Phesi president warns that “flaws are being scaled, not solved” as AI tools rely on historical protocol templates without patient data or contextBoston, USA, 13 May 2026. Phesi, a ...
Data highlight advancements across ElevateBio's targeted gene insertion platform, powered by retrotransposon and machine learning-optimized recombinase approaches, and its new epigenetic editing platf...
Thu, May 14, 2026 12:41 CETReport this content Lioness Medtech AB (publ) will be exhibiting at ESTRO (European Society for Radiotherapy and Oncology) 2026, taking place from 15-18 May 2026 at Stockhol...
Research explores evolving treatment patterns, data quality and equity in community careBOSTON & PHILADELPHIA--(BUSINESS WIRE)-- Ontada®, a McKesson business dedicated to real-world oncology data and ...
New capsids Dyno-9zh and Dyno-n96 for central nervous system (CNS) and muscular gene delivery expand Dyno's portfolio of AI-engineered vectors and create more delivery options for therapeutic develope...
